The booming GLP-1 space was built on weekly injections. In 2026, new obesity pills will push the market into its next chapter.Patients are already getting their hands on the first GLP-1 pill for obesity from Danish drugmaker Novo Nordisk — a once-daily drug that shares the same brand name as its popular injection Wegovy. A GLP-1 pill from the company's chief rival Eli Lilly isn't far behind, with a U.S. approval expected within months. For some people, pills may serve as a more convenient — and potentially ...